When bowel cancer spreads to the liver – preparing for surgery

For patients, families, and primary care teams. From the team behind prehabforsurgery.com

If you have been told that your bowel cancer has spread to the liver and that surgery is being considered, this article is for you. The first thing to know – and the most important – is that colorectal liver metastases (CRLM) are no longer the terminal diagnosis they were once thought to be. Modern surgery, modern chemotherapy, and modern image-guided treatments together mean that about half of patients who have their liver metastases removed at a specialist HPB centre are alive and well at five years. For a disease that used to carry a median survival of less than a year, that is a remarkable change.

This article walks through what CRLM actually is, how the decision to operate is made, what the surgery involves, and most importantly what you can do in the weeks before the operation to give yourself the best possible outcome. It is not a substitute for advice from your own team – it is a starting point for the conversations that follow.

This article covers metastatic liver cancer from bowel cancer. For primary liver cancer (HCC), see [the HCC guide →]

New to prehab? Start with our complete guide to what prehab is.

What are colorectal liver metastases?

Cancers that start in the bowel (colon or rectum) can spread to other organs in the body. The liver is the most common destination because the bloodstream draining the bowel – the portal vein – flows directly into the liver. Cancer cells that escape the bowel travel along this route and can lodge in the liver tissue, where they form secondary tumours called metastases. About half of all patients diagnosed with colorectal cancer will develop liver metastases at some point – some at the same time as their primary diagnosis (synchronous), others months or years later (metachronous).

The critical insight that transformed treatment over the past 30 years is this: unlike many other cancers that have spread, colorectal liver metastases can often be CURED by surgical removal, provided the disease in the liver is confined enough to allow safe resection and there is no significant uncontrolled disease elsewhere. The liver is unique in two ways that make this possible – it regenerates after surgery (so removing parts of it is well-tolerated), and the biology of colorectal metastasis is such that the liver is often the only site of spread, at least for a meaningful window of time.

The big idea – CRLM is potentially curable

Historic figures (1980s and earlier) gave patients with CRLM a median survival of 6-12 months with no treatment, and surgery was thought to be of little benefit. Modern figures (2020s, specialist centres) give:

• 5-year survival after curative liver resection: 40–60%

• 10-year survival after curative liver resection: 20–30%

• Median overall survival even for unresectable disease on modern chemotherapy regimens: 25–30 months

This is not because CRLM has become less aggressive. It is because: (1) surgical techniques and patient selection have improved dramatically; (2) modern chemotherapy combinations (FOLFOX, FOLFIRI, FOLFIRINOX, with or without biologics like bevacizumab, cetuximab, panitumumab) can shrink previously unresectable disease into resectable disease; (3) image-guided liver-directed therapies (ablation, Y90 radioembolisation, hepatic artery infusion chemotherapy) extend the toolkit beyond surgery alone; (4) MDT-based care at specialist centres consistently outperforms ad-hoc management.

Who is suitable for liver resection in CRLM?

Three questions are asked at every MDT discussion, and they collectively determine whether resection is offered:

1. Is the disease technically resectable?

All the visible liver disease must be removable while leaving enough functional liver behind (the future liver remnant, FLR). Modern imaging and surgical planning have expanded what counts as technically resectable. Things that used to be “unresectable” are now routinely removed – multiple bilobar metastases, lesions close to major vessels, very large tumours. Specialist HPB centres resect cases that general surgical centres would have declined.

2. Is the underlying liver healthy enough?

Chemotherapy damages the liver – oxaliplatin causes sinusoidal injury, irinotecan can cause steatohepatitis (CASH – chemotherapy-associated steatohepatitis), and prolonged regimens can leave the liver scarred enough that it does not regenerate normally after surgery. The FLR needs to be larger in a chemo-damaged liver – typically 40% rather than the 25-30% acceptable in a healthy liver.

3. Is the disease elsewhere controllable?

If there is uncontrolled disease in other organs (lung, peritoneum, bone), the benefit of removing liver disease is reduced. Modern thinking is more permissive than it was – limited lung metastases can sometimes be addressed alongside the liver disease – but the question of extra-hepatic disease still matters.

The pre-operative assessment journey

Once your case has been discussed at MDT and resection is recommended, you can expect:

• Detailed imaging – CT chest/abdomen/pelvis with contrast; liver MRI with hepatocyte-specific contrast (Primovist / gadoxetate) for fine detail of liver lesions; sometimes PET-CT to look for occult extra-hepatic disease.

• CEA (carcinoembryonic antigen) and CA 19-9 tumour markers – used for trend monitoring.

• Cardiopulmonary exercise testing (CPET) – increasingly used (particularly in the UK) for major hepatectomy; predicts post-operative risk and guides prehab intensity.

• Specialist anaesthetic assessment – particularly important if you have had significant chemotherapy or have other medical conditions.

• Nutritional assessment by a dietitian – CRLM patients are often deconditioned and sometimes sarcopenic from chemotherapy; addressing this pre-operatively materially improves outcomes.

• Discussion of chemotherapy timing – when did the last cycle end, and is more chemotherapy planned after surgery?

• Discussion of the operation itself – open vs laparoscopic vs robotic, expected length, expected hospital stay, expected complications.

This work-up takes 2–6 weeks typically. Use this window actively – it is your prehab opportunity.

Prehab for CRLM – the practical list

CRLM patients differ from other liver surgery candidates in important ways. The prehab list below addresses what is specific to your situation:

1. Recovery from chemotherapy

If you are currently on chemotherapy or have just finished, the timing of the last cycle matters. Most surgeons want at least 4-6 weeks between the last oxaliplatin-containing cycle and surgery to allow the liver to recover from sinusoidal damage. Bevacizumab requires a longer washout (typically 6–8 weeks) because of wound-healing and bleeding risk. Your oncology and surgical teams should agree the timing together – this is one of the most important questions to ask at MDT.

2. Cardiopulmonary fitness

Same single highest-yield intervention as for any major liver surgery. Even 3-4 weeks of structured exercise – brisk walking 30-45 minutes most days, with some interval-style higher-intensity sessions if your team agrees – measurably improves outcomes. Chemotherapy can leave you significantly deconditioned even if you feel reasonably well; CPET will pick this up objectively. If your CPET results are at the lower end, ask about structured prehab programmes – many cancer centres now run these formally.

3. Nutrition – particularly protein and weight stabilisation

Sarcopenia (loss of muscle mass) is very common after chemotherapy and is one of the strongest predictors of post-operative complications. Most patients benefit from increasing protein intake to 1.5g/kg/day for the 4–6 weeks before surgery. A palm-sized portion of meat, fish, eggs, dairy, or legumes at each meal, plus protein-containing snacks. Oral nutritional supplements (Ensure, Fortisip, Aymes) are commonly prescribed for patients who have lost weight during chemotherapy – these are genuinely useful, not just a marketing exercise.

4. Bowel function – especially if your primary tumour is still in situ

If your primary bowel tumour has not yet been removed (this is sometimes the case in synchronous disease – the liver is treated first, the primary later, or vice versa), pay attention to symptoms of obstruction (cramping, distension, change in bowel habit). Tell your team promptly if these develop or worsen. If you have had a colorectal resection already, you may have an established stoma or anastomosis – your prehab dietitian will help you optimise intake despite these constraints.

5. Stoma considerations if relevant

If you have a stoma, ensure your stoma care is well-established and your supplies are stocked ahead of admission. Bring extra supplies to hospital. Liver surgery does not typically involve stoma manipulation, but post-op fluid balance changes can affect output – your stoma nurse should be in the loop.

6. Iron and anaemia

Many patients with colorectal cancer are anaemic from chronic blood loss from the primary tumour or from chemotherapy. Anaemia at the time of liver surgery significantly increases the likelihood of needing blood transfusion. Iron infusion (ferric carboxymaltose or similar) in the 2-4 weeks pre-op can substantially improve haemoglobin levels. Ask your team to check iron studies if not already done.

7. Smoking and alcohol cessation

Stop smoking ideally 8 weeks before surgery; minimum 4 weeks. Stop alcohol completely for at least 4 weeks pre-op. Both are essential for wound healing, infection risk, and liver regeneration – and both are within your control.

8. Practical preparation at home

• Arrange help at home for the first 2–4 weeks post-discharge – laundry, shopping, cooking, lifting

• Stock the freezer with easy-prepare meals high in protein

• Sort financial / work matters early – sick leave forms, insurance notifications, work handover

• If you have small children or care responsibilities, organise cover for at least 2-3 weeks

• Plan for ongoing oncology appointments – adjuvant chemotherapy often follows liver surgery, and the appointment calendar can be substantial

Surgical strategies – what your surgeon may discuss

CRLM has more surgical strategies available than most other indications for liver surgery. Brief overview of what may be discussed:

• Single-stage hepatectomy – all visible liver disease removed in one operation. The most common approach when feasible.

• Two-stage hepatectomy – when disease is bilobar (in both sides of the liver) and removing it all at once would leave too little liver remnant. The smaller side is cleared first; the larger side regenerates; then the larger side is resected.

• Portal vein embolisation (PVE) – blocking the blood supply to the side that will be resected, causing the other side to grow before the definitive operation. Routinely used to increase FLR.

• ALPPS (associating liver partition and portal vein ligation for staged hepatectomy) — a more aggressive technique to grow the FLR faster than PVE; used in selected high-volume HPB centres.

• Simultaneous bowel + liver resection – for some synchronous cases, removing the primary bowel tumour and the liver disease in the same operation is appropriate. Decision is case-by-case at MDT.

• Conversion chemotherapy followed by resection – for patients whose disease was initially called unresectable, chemotherapy can shrink it into the resectable range. This is increasingly common.

• Hepatic artery infusion (HAI) chemotherapy – delivering chemotherapy directly into the hepatic artery via an implanted pump; re-emerging in some specialist centres for high-disease-burden cases.

• Liver transplantation for selected unresectable CRLM – currently an active research area (Norwegian SECA-II trial, ongoing TRANSMET and other studies) but not yet standard practice outside trials.

Your surgeon will discuss which of these applies to your specific case. The good news is that the toolkit is much wider than it was even 10 years ago.

Recovery expectations

Modern liver surgery follows Enhanced Recovery After Surgery (ERAS) principles – early mobilisation, early eating and drinking, minimal opioids, structured discharge planning. Realistic expectations:

• Hospital stay: typically 5-8 days for open major hepatectomy; 3-5 days for laparoscopic or robotic resections

• Days 1–3: pain control, early mobilisation (out of bed within 12–24 hours), reintroduction of diet

• Days 3–7: progressive recovery, removal of drains and lines, increasing mobility, education for discharge

• First week home: short walks, gentle activities, attentive monitoring for any complications

• Weeks 2–6: gradual return to normal activities; many patients return to office-style work at 4–6 weeks

• Months 2–3: full recovery for most; liver regeneration largely complete by 12 weeks

• Adjuvant chemotherapy (if planned): typically starts 6–8 weeks after surgery, runs for 3–6 months

Long-term outlook and ongoing surveillance

After successful resection of CRLM you will be in ongoing surveillance – typically CT scans every 3-6 months for the first 2-3 years, then less frequently. CEA blood tests at each visit. Most recurrences (if they happen) occur in the first 2 years; the longer you go without recurrence, the lower the future risk.

If disease does recur in the liver later, repeat liver resection is often possible – many patients undergo two, three, or even four separate liver operations over a number of years and remain well. The liver’s regenerative capacity continues to support this. Your team will decide each event on its merits at MDT.

Beyond surveillance for recurrence, you will also be screened for new colorectal primary lesions (colonoscopy every 1-5 years depending on individual risk) and for the effects of any ongoing chemotherapy (peripheral neuropathy from oxaliplatin can take many months to improve; some persists long-term).

Resources

• Bowel Cancer UK – bowelcanceruk.org.uk – comprehensive patient information, support line, financial advice

• Irish Cancer Society – irishcancer.ie – patient support, information line, financial advice

• Macmillan Cancer Support – macmillan.org.uk – practical and financial support for UK patients

• Colontown – colontown.org – large online community of colorectal cancer patients, with sub-groups specifically for liver metastases patients

• Beating Bowel Cancer (now part of Bowel Cancer UK) – patient stories, peer support

• Your local hepatobiliary unit’s patient information leaflets – ask for one

Evidence base

Key sources informing this article:

• Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27(8):1386–1422 (with subsequent updates).

• Adam R, Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg 2019;3(1):50–56.

• Schadde E, Ardiles V, Robles-Campos R et al. Early survival and safety of ALPPS: first report of the International ALPPS Registry. Ann Surg 2014;260(5):829–836.

• Kemeny NE, Melendez FDH, Capanu M et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009;27(21):3465–3471.

• Hagness M, Foss A, Line PD et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 2013;257(5):800–806 (SECA-I); SECA-II follow-up papers.

• Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24(13):2065–2072.

• Melloul E, Hübner M, Scott M et al. Guidelines for perioperative care for liver surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. World J Surg 2016;40(10):2425–2440 (with updates).

• NICE – Colorectal cancer (NG151) and updates including liver metastases section.

A final word

Colorectal liver metastases is one of the genuinely transformed diagnoses in modern oncology. A diagnosis that was once almost universally terminal is now potentially curable for a significant proportion of patients – and even where cure is not the goal, the average length and quality of life on modern treatment is many years longer than it used to be. The weeks before surgery are time you can spend actively improving your odds: optimise fitness, stabilise weight, manage anaemia, stop smoking and drinking, time chemotherapy carefully with your team. Patients who arrive at surgery having done this work recover faster, have fewer complications, and are more likely to go on to complete the full treatment journey (which often includes adjuvant chemotherapy after surgery).

If anything in this article does not match what your own team is telling you, follow your team’s advice for your particular situation. This is a general guide; your care is specific.

Reviewed by Mr Tom Gallagher, Consultant HPB Surgeon, St Vincent’s Healthcare Group, Dublin. Last updated 31 May 2026.